Enzo Biochem

These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information and are distributed in the United States and internationally. The Company operates through three segments: Enzo Life Sciences, Enzo Clinical Labs and Enzo Therapeutics. Enzo Life Sciences segment manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers around the world. Enzo Clinical Labs segment provides diagnostic services to the healthcare community. Enzo Therapeutics segment conducts research and development activities for therapeutic drug candidates.
Company Growth (employees)
Type
Public
HQ
New York, US
Founded
1976
Size (employees)
446 (est)
Website
enzo.com
Enzo Biochem was founded in 1976 and is headquartered in New York, US

Enzo Biochem Office Locations

Enzo Biochem has an office in New York
New York, US (HQ)
527 Madison Ave

Enzo Biochem Data and Metrics

Enzo Biochem Financial Metrics

Enzo Biochem's revenue was reported to be $27.1 m in Q3, 2017
USD

Revenue (Q3, 2017)

27.1 m

Net income (Q3, 2017)

(2.6 m)

EBIT (Q3, 2017)

(227 k)

Market capitalization (18-Aug-2017)

499.8 m

Cash (30-Apr-2017)

62.6 m
Enzo Biochem's current market capitalization is $499.8 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

93.7 m95.9 m97.6 m102.8 m

Revenue growth, %

2%2%5%

R&D expense

3.5 m

Operating expense total

112.7 m106.1 m98.8 m55.8 m

EBIT

(19 m)(10.2 m)(1.2 m)47 m

EBIT margin, %

(20%)(11%)(1%)46%

Interest expense

54 k208 k245 k136 k

Pre tax profit

(18.9 m)(9.9 m)(2.3 m)46.5 m

Income tax expense

(712 k)72 k(7 k)1.2 m

Net Income

(18.2 m)(10 m)(2.3 m)45.3 m
USDQ1, 2014Q2, 2015Q3, 2015Q1, 2015Q2, 2016Q3, 2016Q1, 2016Q2, 2017Q3, 2017

Revenue

24.8 m23.1 m24 m25.2 m24.6 m26.4 m26.3 m26.3 m27.1 m

R&D expense

791 k834 k809 k867 k861 k882 k822 k483 k766 k

General and administrative expense

11.2 m10.5 m

Operating expense total

791 k834 k809 k867 k861 k882 k822 k11.6 m11.3 m

EBIT

(3.1 m)(3.9 m)(2.8 m)4.6 m7.5 m(2.5 m)(1.3 m)(1 m)(227 k)

EBIT margin, %

(12%)(17%)(12%)18%30%(10%)(5%)(4%)(1%)

Interest expense

(69 k)(49 k)(58 k)(40 k)(42 k)(40 k)46 k79 k115 k

Pre tax profit

(3.6 m)(4.2 m)(3 m)4.5 m7 m(2.1 m)(1.5 m)(1 m)(39 k)

Income tax expense

(123 k)(87 k)(207 k)(2 k)(20 k)(53 k)(32 k)

Net Income

(3.7 m)(7.8 m)(10.7 m)4.4 m11.3 m9.2 m(1.5 m)(2.5 m)(2.6 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

9 m17.5 m18.1 m67.8 m

Accounts Receivable

12.3 m12.5 m6.7 m6.7 m

Inventories

8.8 m8.7 m7.4 m7 m

Current Assets

32.6 m40.7 m46.5 m91.4 m

PP&E

8.6 m7.7 m7.9 m8.2 m

Goodwill

7.5 m7.5 m7.5 m7.5 m

Total Assets

59 m64.4 m68.4 m111.8 m

Current Liabilities

23.9 m25 m24 m20.6 m

Total Liabilities

22.3 m

Additional Paid-in Capital

304.3 m317.2 m325 m326.3 m

Retained Earnings

(272.4 m)(282.4 m)(284.7 m)(239.4 m)

Total Equity

34.1 m37 m42.6 m89.6 m

Financial Leverage

1.7 x1.7 x1.6 x1.2 x
USDQ1, 2014Q2, 2015Q3, 2015Q1, 2015Q2, 2016Q3, 2016Q1, 2016Q2, 2017Q3, 2017

Cash

16.6 m15.3 m14.4 m30.6 m37 m32.4 m67.2 m62.4 m62.6 m

Accounts Receivable

6.7 m6.7 m

Inventories

8.5 m8.3 m8 m7.6 m7.4 m7 m7.2 m7.1 m7.2 m

Current Assets

39.7 m37 m36.1 m52.8 m59.2 m55.2 m90.4 m86.9 m87.5 m

PP&E

7.5 m7.6 m8 m8.1 m8.7 m8.6 m8.3 m8.2 m8.1 m

Goodwill

7.5 m7.5 m7.5 m7.5 m7.5 m7.5 m7.5 m7.5 m7.5 m

Total Assets

62.6 m59.5 m58.5 m74.4 m80.9 m76.5 m110.5 m106.4 m106.6 m

Current Liabilities

24.5 m22.7 m22.5 m25.8 m24.5 m21.7 m20.8 m17.6 m17 m

Additional Paid-in Capital

319.9 m322.7 m324.9 m325.1 m325.3 m326.1 m326.4 m326.8 m327.8 m

Retained Earnings

(286.1 m)(290.2 m)(293.1 m)(280.2 m)(273.4 m)(275.5 m)(240.9 m)(241.9 m)(242 m)

Total Equity

47.2 m54.4 m53 m88.5 m87.7 m88.6 m

Financial Leverage

1.6 x1.5 x1.4 x1.2 x1.2 x1.2 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(18.2 m)(10 m)(2.3 m)45.3 m

Accounts Receivable

(2.6 m)(3.2 m)(2 m)(4.8 m)

Inventories

60 k159 k1.2 m466 k

Cash From Operating Activities

(10 m)(1.7 m)(3.7 m)53.1 m

Capital Expenditures

(988 k)(838 k)(1.8 m)(1.5 m)

Cash From Investing Activities

(971 k)(833 k)(1.8 m)(1.5 m)

Cash From Financing Activities

4.8 m10.9 m6.2 m(1.9 m)

Free Cash Flow

(11 m)(2.5 m)(5.5 m)51.6 m
USDQ1, 2014Q2, 2015Q3, 2015Q1, 2015Q2, 2016Q3, 2016Q1, 2016Q2, 2017Q3, 2017

Net Income

(3.7 m)(7.8 m)(10.7 m)4.4 m11.3 m9.2 m(1.5 m)(2.5 m)(2.6 m)

Accounts Receivable

(482 k)(524 k)(940 k)(1.4 m)(2 m)(3 m)(150 k)(2.2 m)(3.2 m)

Inventories

107 k306 k597 k(210 k)(20 k)447 k(298 k)(238 k)(213 k)

Cash From Operating Activities

(2.8 m)(6.5 m)(8.2 m)13.2 m20.1 m17 m(333 k)(2.8 m)(1.9 m)

Capital Expenditures

(264 k)(653 k)(1.2 m)(505 k)(943 k)(1.4 m)(514 k)(689 k)(1.4 m)

Cash From Investing Activities

(259 k)(653 k)(1.2 m)(490 k)(941 k)(1.4 m)(514 k)(687 k)(1.4 m)

Cash From Financing Activities

2.2 m5.1 m6.4 m(125 k)(192 k)(1.4 m)303 k(1.8 m)(1.8 m)

Free Cash Flow

(3 m)(7.1 m)(9.3 m)12.6 m19.1 m15.6 m(847 k)(3.5 m)(3.3 m)
Y, 2017

Financial Leverage

1.2 x

Enzo Biochem Operating Metrics

FY, 2016

Patents Issued

314

Patents Pending

146

Facilities

2

Enzo Biochem Market Value History

Enzo Biochem Revenue Breakdown

Traffic Overview of Enzo Biochem

Enzo Biochem Company Life and Culture

You may also be interested in